Literature DB >> 14535879

Gastric acid-suppressive therapy and community-acquired respiratory infections.

R J F Laheij1, M C Van Ijzendoorn, M J R Janssen, J B M J Jansen.   

Abstract

BACKGROUND: Bacteria and viruses have been detected in the stomach of patients during acid-suppressive therapy. AIM: To investigate whether subjects using acid-suppressive drugs more often develop community-acquired respiratory infections when compared to those who do not use acid-suppressive drugs.
METHODS: 700 study subjects were recruited during a single week in December 2002. Information on the prevalence of clinical manifestations of infections and complications in the preceding month was assessed by questionnaire. Furthermore, subjects were asked to report antibiotic therapy and physician visits related to possible infection.
RESULTS: Questionnaires were returned by 405 subjects (58%). Consumption of acid-suppressive drugs was reported by 91 individuals, of whom 79 used proton-pump inhibitors (20%) and 12 H2-receptor antagonists (3%). Overall, 101 (25%) responders reported clinical manifestations of respiratory infection in the preceding month. Subjects using acid-suppressive drugs were 2.34 times [95% confidence interval (CI) 1.4-4.1] more likely to have clinical manifestations of infection than individuals not using acid-suppressive drugs. Subjects using acid-suppressive drugs visited a physician 3.72 times more often (95% CI 2.1-6.8) for an infection and received antibiotic therapy 4.19 times more often (95% CI 2.2-8.1) in comparison to individuals not using acid-suppressive drugs.
CONCLUSIONS: Subjects using acid-suppressive drugs more often reported community-acquired respiratory infections in comparison to those who did not use acid-suppressive drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14535879     DOI: 10.1046/j.1365-2036.2003.01744.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  20 in total

1.  Inappropriate prescribing of proton pump inhibitors in primary care.

Authors:  Bisanth Thushila Batuwitage; Jeremy G C Kingham; Nia Emma Morgan; Ruth Louise Bartlett
Journal:  Postgrad Med J       Date:  2007-01       Impact factor: 2.401

2.  Community-acquired pneumonia and acid-suppressive drugs: position statement.

Authors: 
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

Review 3.  Potential adverse effects of proton pump inhibitors.

Authors:  Gregory A Coté; Colin W Howden
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 4.  Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials.

Authors:  Nabil Sultan; Jose Nazareno; James Gregor
Journal:  Can J Gastroenterol       Date:  2008-09       Impact factor: 3.522

Review 5.  Proton-pump inhibitors: understanding the complications and risks.

Authors:  Peter Malfertheiner; Arne Kandulski; Marino Venerito
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 6.  Gastroesophageal reflux disease in children and adolescents: when and how to treat.

Authors:  Matthew W Carroll; Kevan Jacobson
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

Review 7.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 8.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

Review 9.  Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.

Authors:  Chun-Sick Eom; Christie Y Jeon; Ju-Won Lim; Eun-Geol Cho; Sang Min Park; Kang-Sook Lee
Journal:  CMAJ       Date:  2010-12-20       Impact factor: 8.262

10.  Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary-care providers.

Authors:  B M R Spiegel; M Farid; M G H van Oijen; L Laine; C W Howden; E Esrailian
Journal:  Aliment Pharmacol Ther       Date:  2009-01-15       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.